Hetero

Hetero Biopharma is a biopharmaceutical company founded in 2009, focused on developing and manufacturing affordable, high-quality medicines to broaden access to treatment worldwide. Supported by a robust research and development ecosystem and advanced manufacturing facilities, the company works across monoclonal antibodies, recombinant proteins, antibody-drug conjugates, vaccines, cell and gene therapies, single-use solutions, and small-molecule products.

Biosimilars are central to Hetero Biopharma’s portfolio and mission. The company presents them as high-quality alternatives to reference biologics, with comparable safety, efficacy, and therapeutic outcomes, helping make important therapies more accessible and support health equity. Its products address conditions including cancer, rheumatoid arthritis, other inflammatory diseases, anaemia, acute myocardial infarction, and multiple myeloma. Notable biosimilars include Derise (darbepoetin alfa), Rilast (rituximab), Bevaas (bevacizumab), Pamera (adalimumab), Sezuma (trastuzumab), TNKPLASE (tenecteplase), Pegalsa (pegylated asparaginase), Aspalsa (L-asparaginase), and Denotec (denosumab). Hetero Biopharma emphasizes global quality standards, manufacturing capability, and expanding access to biologic therapies.